Translational advances in pancreatic ductal adenocarcinoma therapy
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer entity characterized by a
heterogeneous genetic landscape and an immunosuppressive tumor microenvironment …
heterogeneous genetic landscape and an immunosuppressive tumor microenvironment …
[HTML][HTML] Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
JH Strickler, H Satake, TJ George… - New England journal …, 2023 - Mass Medical Soc
Abstract Background KRAS p. G12C mutation occurs in approximately 1 to 2% of pancreatic
cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated …
cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated …
[HTML][HTML] Pancreatic cancer in 2021: What you need to know to win
V Tonini, M Zanni - World Journal of Gastroenterology, 2021 - ncbi.nlm.nih.gov
Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …
Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions
Simple Summary Tumor mutational burden (TMB) represents the number of mutations per
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …
Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age
PJ Trivedi, H Crothers, J Mytton, S Bosch, T Iqbal… - Gastroenterology, 2020 - Elsevier
Background & Aims There are insufficient population-level data on the effects of primary
sclerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD). Methods We …
sclerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD). Methods We …
Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems
Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …
Facts and hopes in immunotherapy of pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to
treat. For patients with advanced and metastatic disease, chemotherapy has yielded only …
treat. For patients with advanced and metastatic disease, chemotherapy has yielded only …
Immunotherapy in pancreatic cancer: why do we keep failing? A focus on tumor immune microenvironment, predictive biomarkers and treatment outcomes
A Di Federico, M Mosca, R Pagani, R Carloni, G Frega… - Cancers, 2022 - mdpi.com
Simple Summary In pancreatic cancer, immunotherapy and targeted therapies have not
brought about the therapeutic revolution that has been observed in other malignancies …
brought about the therapeutic revolution that has been observed in other malignancies …
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
C Luchini, G Paolino, P Mattiolo, ML Piredda… - Journal of Experimental …, 2020 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait
is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases …
is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases …